Trial Profile
Phase Ib Study of MEK162 in Combination With Capecitabine in Gemcitabine-pretreated Advanced Biliary Tract Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Capecitabine (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2019 Status changed from active, no longer recruiting to completed.
- 17 Jul 2019 Primary endpoint (Progression-free survival (PFS)) has not been met as per results published in the British Journal of Cancer
- 17 Jul 2019 Results published in the British Journal of Cancer